Focused Wealth Management’s Celldex Therapeutics CLDX Stock Holding History

Focused Wealth Management’s Portfolio CLDX Stock Details CLDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-23	Closed	–	–	782
2020 Q2	$0	Hold	23	–	–	﹤0.01%	762
2020 Q1	$0	Hold	23	–	–	﹤0.01%	714
2019 Q4	$0	Hold	23	–	–	﹤0.01%	721
2019 Q3	$0	Hold	23	–	–	﹤0.01%	707
2019 Q2	$0	Hold	23	–	–	﹤0.01%	736
2019 Q1	$0	Hold	23	–	–	﹤0.01%	704
2018 Q4	$0	Hold	23	–	–	﹤0.01%	695
2018 Q3	$0	Hold	23	–	–	﹤0.01%	662
2018 Q2	$0	Hold	23	–	–	﹤0.01%	676
2018 Q1	$1K	Hold	23	–	–	﹤0.01%	652
2017 Q4	$1K	Buy	+23	New	+$985	﹤0.01%	637

Other funds holding CLDX

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

ACP

Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return

Focused Wealth Management's CLDX Position: Q3 2020 in Review

Focused Wealth Management sold out of Celldex Therapeutics (CLDX) in Q3 2020, closing a stake of 23 shares.

Focused Wealth Management first reported a position in CLDX in Q4 2017 and held it in 11 quarters. The position peaked at $1K in Q1 2018. 91 funds tracked by Wall St. Rank hold CLDX as of Q3 2020.

Focused Wealth Management reported no remaining Celldex Therapeutics position as of Q3 2020 after selling out during the quarter.
Focused Wealth Management sold 23 Celldex Therapeutics shares in Q3 2020.
Focused Wealth Management first reported a position in Celldex Therapeutics in Q4 2017 and held it in 11 quarters.
Focused Wealth Management's Celldex Therapeutics position peaked at $1K in Q1 2018.
91 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q3 2020.

Based on Focused Wealth Management's 13F filing for Q3 2020, filed 19 Oct 2020.